N-003 (ambrisentan) is not approved for commercialisation
© — Noorik Biopharmaceuticals, Switzerland
Liver Cirrhosis results from chronic liver diseases, such as NASH, hepatitis and Alcohol Liver Disease. About 40,000 people die of the complications of cirrhosis every year. Although liver transplantation is an option for some, a significant number of patients will die while waiting for a suitable organ. The cost of treating advanced liver disease and cirrhosis is estimated at USD 10Bn per year.
Portal Hypertension is the precursor to the major complications of cirrhosis: ascites, upper gastrointestinal varices, hepatic encephalopathy, infection and renal failure. Portal Hypertension is a deadly and costly condition. There are no approved drugs for the treatment of Portal Hypertension.
N-003 is a proprietary formulation of ambrisentan which is currently being evaluated as a treatment of Portal Hypertension. Ambrisentan and other endothelin receptor antagonists have been shown to reduce intra-hepatic resistance and portal pressure and increasing liver blood flow.
We strongly believe that endothelin is a target of enormous potential for the treatment of human disease. Our focus is to transform this conviction into a treatment for patients.